Optimi Health CORP F-1 registration statements

Optimi Health Corp. has filed an amendment to its F-1 registration statement with the SEC, detailing plans for an initial public offering of 2,500,000 common shares, aiming for a Nasdaq Capital Market listing.

Optimi Health Corp. is seeking to list on the Nasdaq Capital Market, offering 2.5 million common shares to fund production scaling and market expansion.

Optimi Health Corp. has filed an amendment to its F-1 registration statement, primarily to update the filing fee table.

Optimi Health Corp. has filed an amendment to its F-1 registration statement with the SEC, detailing its initial public offering of 2.5 million common shares in the United States.

Optimi Health Corp. has filed an F-1/A registration statement for an initial public offering of 2,500,000 units on the Nasdaq Capital Market.

Optimi Health Corp. filed an F-1/A registration statement for an initial public offering of 2.5 million common shares on Nasdaq, aiming to expand its psychedelic pharmaceutical business into the U.S. and Israel while reporting continued operating losses.

Optimi Health Corp., a Canadian GMP-compliant psychedelic drug manufacturer, is launching an initial public offering in the United States and applying for a Nasdaq listing, despite a history of operating losses and significant regulatory hurdles.

Optimi Health Corp., a Canadian GMP-compliant psychedelic drug manufacturer, files an F-1 registration statement for a U.S. IPO and Nasdaq Capital Market listing, aiming to expand into U.S. and Israeli markets.